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Bone marrow-derived mononuclear cells (BMMNCs) are
being tested clinically to enhance postischemic neovas-
cularization; however, cardiovascular risk factors such as
diabetes and high cholesterol counteract the pro-angio-
genic potential of BMMNCs. Mees et al (Am J Pathol
2011, 178:55–60) hypothesized that endothelial NO syn-
thase (eNOS), which is pro-angiogenic, could restore the
neovascularization response of BMMNCs. Overexpres-
sion of eNOS in diabetic or atherosclerotic (ApoE-knock-
out) BMMNCs restored their pro-angiogenic potential for
treating ischemic mice, with BMMNCs differentiating into
cells exhibiting an endothelial phenotype such as
VEGF-A release and NO-mediated vasodilation. More-
over, eNOS-expressing ApoE-knockout BMMNCs had
antiatherogenic effects. Thus, cell-based eNOS gene
therapy has potential for treating ischemic cardiovascular
disease.
Bile Acids Induce Liver Inflammation
Inflammation contributes to liver injury during bile duct
blockage, or cholestasis, but the mechanism is not
known. Two possible mechanisms of injury were investi-
gated by Allen et al (Am J Pathol 2011, 178:175–186): 1)
Toll-like receptor 4 (TLR4) activated by bacteria or dead
hepatocytes, and 2) bile acids acting as inflammagens.
Liver inflammation following bile duct ligation (BDL) was
not abrogated in mice with an inactive TLR4. Bile acids,
on the other hand, increased expression of proinflamma-
tory cytokines, chemokines, and adhesion molecules in
hepatocytes exposed in vitro. Up-regulation of several of
these genes in hepatocytes and in BDL mouse livers
required early growth response factor-1 (Egr-1). Further,
the livers of patients with cholestasis displayed Egr-1
up-regulation that correlated with levels of inflammatory
mediators. These data demonstrate that bile acids, not
TLR4, directly promote hepatic inflammation during cho-
lestasis.
Do Proteasome Inhibitors Kill Cancer Cells
via p53?
Inhibitors of the cell’s protein degradation complex, the
proteasome, are used to treat cancer, but their mecha-
nisms of action are not clearly understood. Pandit et al
(Am J Pathol 2011, 178:355–360) examined the role of
tumor suppressor p53, which is frequently mutated incancer, in proteasome inhibitor-induced apoptosis since
p53 has been implicated to play a role in several studies.
Surprisingly, proteasome inhibitors induced p53-inde-
pendent apoptosis in human cancer cell lines that corre-
lated with induction of proapoptotic protein Noxa, which
is p53 independent. These drugs also inhibited growth of
cancer cell lines from different sources (colon, breast,
and liver) independently of p53 status. These unex-
pected results stress the importance of performing addi-
tional experiments to explain the discrepant roles of p53
in proteasome inhibitor-induced apoptosis.
Fibrosis IZ Key to Breast Cancer Invasion
Dense fibrosis commonly occurs in invasive ductal breast
cancer and may represent an altered tumor microenvi-
ronment (TME) that precedes tumor invasion. Kim et al
(Am J Pathol 2011, 178:373–381) characterized the dense
fibrotic zone of invasive ductal carcinoma, postulating the
presence of an interface zone (IZ) encircling the tumor
margin and overlapping the normal tissue. The extracel-
lular matrix component laminin-332 was specifically over-
expressed in the IZ, together with MMP3, MT1-MMP,
Snail, and ZEB1, demonstrating alterations in TME re-
lated to fibrosis and tumor invasion. Myofibroblasts iso-
lated from the IZ displayed laminin-332 and MT1-MMP
overexpression. Thus, the fibrotic IZ may be the actual
tissue site of TME and may provide a specialized micro-
environment for guiding tumor invasion.
Tregs Target Hypertension and Heart Disease
The cellular and molecular mechanisms of hypertension-
complicated coronary artery disease are not well under-
stood, but immune cells and inflammation have been
implicated. Since CD4CD25 regulatory T cells (Tregs)
have been reported to regulate heart fibrosis in hyperten-
sion, Matrougui et al (Am J Pathol 2011, 178:434–441)
examined the role of Tregs in an angiotensin II (Ang-II)-
dependent hypertensive mouse model. Ang-II-mice dis-
played macrophage activation/infiltration into coronary
arterioles and heart as well as increased local TNF-
release. Hypertensive mice injected with control Tregs,
however, exhibited reduced macrophage activation and
infiltration, TNF- release, and improved coronary arteriolar
endothelium-dependent relaxation. These data indicate that
Tregs are involved in the development of coronary arteriolar
endothelial dysfunction in hypertension.
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